New study highlights the bone forming and antiresorptive effects of romosozumab in postmenopausal women with osteoporosis.
About Lifestyle and Osteoporosis
Encyclopedia section of medindia briefly explains about Lifestyle and Osteoporosis
Encyclopedia section of medindia briefly explains about Lifestyle and Osteoporosis
‘Romosozumab, an antibody therapy that targets sclerostin, is the first osteoporosis therapy with a dual effect on bone tissue, increasing bone formation, and decreasing resorption.’
Read More..
Romosozumab increases serum markers of bone formation and decreases those of bone breakdown, or resorption. This is associated with an increased bone mineral density and a reduced risk of bone fractures.Read More..
This latest analysis included 107 patients with osteoporosis who were enrolled in the multicenter, phase 3 clinical trial called the Fracture Study in Postmenopausal Women with Osteoporosis (FRAME) study and who underwent bone biopsies. The analysis showed that at the tissue level, romosozumab produced an early and transient increase in bone formation and a persistent decrease in bone resorption. This led to significant increases in bone mass and improved bone microarchitecture (Figure) after 12 months of therapy. These effects contribute to the reduced fracture risk previously reported in postmenopausal women with osteoporosis treated with romosozumab.
"Romosozumab is the first osteoporosis therapy with a dual effect on bone tissue, increasing bone formation and decreasing resorption" said lead author Dr. Pascale Chavassieux, of the University of Lyon, in France.
Osteoporosis-Causes-Symptoms-Diagnosis-Treatment-FAQs
Osteoporosis is a bone disease that leads to an increased risk of fractures. The bone mass is reduced and the bones are porous, thereby resulting in weakness of the skeletal system of the body.
Osteoporosis is a bone disease that leads to an increased risk of fractures. The bone mass is reduced and the bones are porous, thereby resulting in weakness of the skeletal system of the body.
Romosozumab Increases Bone Mineral Density, Bone Content Compared With Teriparatide
A new study shows that in postmenopausal women with low bone mass, romosozumab significantly increased bone mineral density and bone content in both the spine and hip compared to baseline, and also compared with the commonly prescribed anabolic agent teriparatide and placebo.
A new study shows that in postmenopausal women with low bone mass, romosozumab significantly increased bone mineral density and bone content in both the spine and hip compared to baseline, and also compared with the commonly prescribed anabolic agent teriparatide and placebo.
Fractures in Osteoporosis can be Reduced with Romosozumab and alendronate
Treatment with the drug romosozumab followed by alendronate reduces the risk of fractures and decreases bone resorption.
Treatment with the drug romosozumab followed by alendronate reduces the risk of fractures and decreases bone resorption.
